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Abstract
Background: Despite the growing numbers of men and women with opioid use disorder in Canada, sex-specific
issues in treatment have not been re-examined in the current population of patients with opioid addiction. We
aimed to evaluate sex differences in substance use, health, and social functioning among men and women
currently receiving methadone treatment for opioid use disorder in Ontario, Canada.
Methods: We recruited 503 participants with opioid dependence disorder receiving methadone maintenance
treatment. We collected data on demographics, treatment characteristics, psychiatric history, addiction severity, and
drug use patterns through urinalysis. We performed adjusted univariate analyses and logistic regression to identify
distinct factors affecting men and women.
Results: Among our sample of 54 % (n = 266) men and 46 % women (n = 226) with mean age 38.3 years, less than
half of participants were employed (35.6 %) and married (31.8 %) and had completed a high school education
(27.9 %). Compared to men, women had frequent physical and psychological health problems, family history of
psychiatric illness, and childcare responsibilities and began using opioids through a physician prescription. Men had
higher rates of employment, cigarette smoking, and cannabis use compared to women.
Conclusions: Our results have revealed different patterns of substance use, health, and social functioning among
men and women currently receiving methadone treatment for opioid addiction in Ontario, Canada. This
information can be used to develop an integrative treatment regimen that caters to the individual needs of men
and women, as well as to inform methadone treatment protocols to include specialized services (including
vocational counseling, childcare and parenting assistance, medical assistance, relationship or domestic violence
counseling, etc.) and increase their availability and accessibility on a larger scale.
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Background
The last decade has witnessed significant changes in pat-
terns of illicit opioid use in Canada [1]. Increases in the
availability and utilization of opioids for the manage-
ment of pain conditions in primary care settings [2] have
resulted in the shift from heroin use to non-medical pre-
scription opioid use [3]. The number of opioid prescrip-
tions has more than doubled over the last two decades
[4, 5] and has been associated with a significant burden
of opioid-related mortality nationwide with highest rates
reported in Ontario [6–8]. Currently ranking first in glo-
bal opioid analgesic consumption [9], Canadians are at a
heightened risk for opioid abuse and dependence, giving
rise to a major public health crisis [10].
Higher rates of prescription opioid use among women
have been consistently documented across studies in
Canada and the USA [3, 11–14]. Patterns of opioid pre-
scribing are higher among women [15], who are more
likely than men to suffer from poor health including
pain conditions [16], making them especially vulnerable
to misuse prescription narcotics. Indeed, the number of
women seeking treatment for opioid-related disorders
has markedly increased since the 1960s, reaching current
levels that are comparable to men [17].
With the rising number of women seeking treatment
for opioid-related problems, there is growing need for a
re-evaluation of sex and gender differences in opioid de-
pendence and treatment. Methadone maintenance treat-
ment (MMT) is the most common form of opioid
agonist therapy implicated for the management of opioid
use disorders and currently serves over 35,000 patients
in Ontario alone, a pronounced increase compared to
7800 in 2001 [18–20]. However, most of what we cur-
rently know about methadone treatment is based pri-
marily on studies that included few or no women at all
[21, 22]. Existing treatment options remain targeted to-
wards opioid users of the past; primarily young, inner-
city, heroin-injecting men. Despite the demographic
transformation of this population, available prevention
strategies and treatment options have not been revised
to accommodate these developments.
The identification of these sex- and gender-specific
patterns has been imperative for informing standards of
care and clinical practice thus far, however many of
these studies were completed in the 1990s and are not
representative of today’s population of opioid users, nor
have they accounted for advancements in assessment
tools and research methodology. There is a critical need
for a thorough re-evaluation of sex-related factors for
men and women with opioid use disorder. Our objec-
tives in this study are to (1) provide an updated and ex-
tensive description of the current population of opioid
users in methadone treatment in Ontario, Canada, and
(2) evaluate sex differences in substance use, health
status, and social functioning among men and women
currently receiving methadone treatment for opioid use
disorder.
Methods
Study design and participant recruitment
We collected data for this study as part of the Genetics
of Opioid Addiction (GENOA) research program, in col-
laboration with Canadian Addiction Treatment Centres
(CATC; formerly known as Ontario Addiction Treat-
ment Centres or OATC) and the Population Genomics
Program (PGP) at McMaster University. Details of study
methods have been reported previously [23–25]. We
have since expanded our recruitment setting to include
13 opioid agonist treatment clinics.
We screened all eligible candidates for study inclusion.
Participants were included in the study if they were
≥18 years of age, meeting criteria for DSM-IV opioid de-
pendence disorder, attending CATC clinics for metha-
done treatment, and able to provide written consent and
blood samples. Participants attending the clinics for opi-
oid agonist treatment other than methadone were not
eligible for this study. We chose to include only patients
who are receiving methadone treatment as this is the
most common opioid agonist treatment in Canada and
is covered by most provincial health insurance plans,
which allows us to recruit the largest sample possible.
Other opioid maintenance treatments (e.g., buprenor-
phine, naltrexone) are less commonly used and also have
distinct biochemical and physiological properties, which
would increase the heterogeneity among the sample and
render our findings less applicable to the opioid patient
population as a whole.
Upon agreeing to participate in the study, participants
provided informed consent and underwent baseline as-
sessment, which consisted of a structured clinical inter-
view administered by trained research staff. We collected
self-reported data on demographics, treatment character-
istics, age of initial opioid use, and psychiatric history. We
also collected information on drug use patterns, measured
through urinalysis, and addiction severity across multiple
domains using the MAP tool. This study was approved by
the Hamilton Integrated Research Ethics Board (HIREB;
Study ID 11–056).
Maudsley Addiction Profile (MAP)
We used the MAP instrument [26] to measure function-
ing across several life domains related to addiction; sub-
stance use, physical and psychological health symptoms,
health risk behavior, and social functioning. The MAP
evaluates numerous outcomes, which are common indi-
cators of treatment performance in substance use disor-
ders. Outcomes are evaluated based on the previous
month. Originally developed in 1998 for patients with
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substance use disorders in the UK, it is now widely used
and has demonstrated internal reliability and validity
[26].
Data on substance use (including alcohol, heroin, illicit
methadone, illicit benzodiazepines, cocaine/crack, am-
phetamines, and cannabis) including the number of days
of use, amount, and route of administration was collected
for the previous 30-day period. The health risk behavior
domain assessed injection drug use, including number of
days and frequency of sharing injecting equipment, as well
as sexual behavior, including frequency of unprotected sex
and number of sexual partners in the previous 30-day
period. Frequency of physical and psychological health
symptoms were assessed on a scale ranging from “Never”
to “Always”; these responses were tabulated into a single
score out of total score of 40, with higher values indicating
more frequent health problems. The social functioning
domain consisted of interpersonal conflict (days of contact
and conflict with partner, family, and friends; represented
as a proportion of days of conflict over days of contact in
the analysis), employment (days employed and days
missed from work), and criminal activity (number of days
committed crime and number of times daily). Crime
included selling drugs, fraud/forgery, shoplifting, and
theft from property or vehicle. For analysis purposes,
these were combined into a single variable represent-
ing any crime.
Substance use
We collected data on weekly/bi-weekly qualitative and
semiquantitative urine analysis using the iMDx™ Analyzer
and Prep Assay (NOVX Systems Inc, Richmond Hill, On-
tario, Canada). Urine drug screens are used as part of the
clinical care model to monitor methadone adherence, as
well as to identify the use of illicit opioids and other sub-
stances of abuse (including cocaine, cannabis, and benzodi-
azepines). The cut-off concentrations for detection by
urinalysis were the following: 300 ng/ml for opiates, benzo-
diazepines, benzoylecgonine (cocaine metabolite), 100 ng/
ml for oxycodone, and 50 ng/ml for tetrahydrocannabinol
(THC). The iMDx™ assay is designed to distinguish be-
tween opioid classifications, including naturally-occurring
and synthetic opioids. Urine samples were obtained and
analyzed by trained clinic staff at the methadone
clinic sites.
In this study, substance use behavior (including opioids,
amphetamines, benzodiazepines, cannabis, and cocaine)
was measured as the percent of positive urine screens per
total number of available urine screens for each respective
drug of interest over the previous three-month period.
Alcohol abuse and dependence were measured according
to the Mini International Neuropsychiatric Interview
(M.I.N.I.) Version 6.0 [27]. Self-reported drug use in the
past 30 days was collected using the MAP.
Statistical analysis
We summarized descriptive sample characteristics using
mean (standard deviation, SD) for continuous measures
and number (percentage) for categorical variables. For
variables with non-normal distributions, we reported
median and interquartile range (Q1 and Q3). We per-
formed adjusted univariate analyses on substance use be-
havior, health symptoms, and social functioning to test
differences between men and women (defined as their
biological sex) using multivariable linear regression for
continuous variables and logistic regression for binary
variables, while controlling for age, methadone dose, and
duration of methadone treatment. Variables with non-
normal distributions were log transformed prior to the
analysis and differences were reported on the log scale.
The primary outcome was opioid use measured through
urine drug screening; all other outcomes were second-
ary. We used the false discovery rate (FDR) [28] method
to control type 1 error rate when performing multiple
comparison and adjusted p values accordingly. A sensi-
tivity analysis was completed using the self-reported
MAP assessment to measure substance use compared to
urine drug screening. Regression model estimates in-
cluding odds ratio (OR) for binary variables, mean differ-
ence (MD) for continuous variables, 95 % confidence
intervals (CI), and p values (adjusted for covariates and
multiple testing) are reported.
We did not employ imputations for missing data in
our analysis as the proportion of missing data was negli-
gible (4.1 %) [29]. Our sample size was adequately pow-
ered to perform multivariable logistic regression with 10
events per variable and 16 covariates in a sample of 226
women [30]. We used STATA Version 12 (StataCorp LP,
College Station, USA) for all statistical analyses and we
reported this study in adherence to the Strengthening
the Reporting of Observational Studies in Epidemiology
(STROBE) guidelines [31].
Results
We recruited a total of 503 participants receiving opioid
agonist treatment from 13 CATC clinics. Among them,
three participants were excluded because they had
switched to treatment with buprenorphine rather than
methadone. Further, eight participants were excluded as
a result of failure to obtain blood and urine samples. A
total of 492 participants were included in subsequent
analyses (Fig. 1).
Demographic and clinical characteristics
Our sample consisted of 54 % (n = 266) men and
46 % women (n = 226), with a mean age of 38.3 years
and mean methadone dose of 77.6 mg (SD = 44.1).
Less than half of participants were employed (35.6 %)
and had completed a high school education (27.9 %).
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Age of initial regular opioid use was 25 years and age
of first entry into methadone treatment was 32.2 years
among the total sample. Almost half (44.2 %) re-
ported that their first contact with opioids was
through a doctor’s prescription for a medical illness
(Table 1).
Women were younger than men (36.9 years vs.
39.5 years) and receiving a lower methadone dose
(73.3 mg vs. 81.3 mg). Women also more commonly re-
ported having had their first contact with opioids
through a physician prescription (Table 1). Men and
women were similar in their age of first regular opioid
Fig. 1 Eligibility and screening of candidates for inclusion in the GENOA study
Table 1 Demographic and clinical characteristics of opioid-dependent men and women receiving methadone treatment
Sex
Characteristic Total Men Women
n = 492 n = 266 n = 226
Age, years; mean (SD) 38.3 (11.0) 39.5 (11.7) 36.9 (9.9)
European ethnicity; n (%) 393 (80.9) 219 (83.0) 174 (78.4)
Completed high school education; n (%) 136 (27.9) 65 (24.6) 71 (32.0)
Substance use and treatment history
Age of initial opioid use, years; mean (SD) 25.0 (8.7) 24.9 (9.2) 25.1 (8.0)
Physician prescribed first opioid use; n (%) 217 (44.2) 100 (37.7) 116 (51.6)
Daily methadone dose, milligram; mean (SD) 77.6 (44.1) 81.3 (48.3) 73.3 (38.3)
Age of first MMT, years; mean (SD) 32.2 (9.6) 32.7 (10.1) 31.5 (9.0)
Duration of MMT, months; mean (SD) 51.6 (49.3) 52.9 (50.7) 49.9 (47.7)
Previous treatment, any; n (%) 149 (30.7) 90 (34.2) 59 (26.6)
Previous MMT treatments, number; mean (SD) 1.5 (1.1) 1.6 (1.1) 1.4 (0.9)
SD standard deviation, MMT methadone maintenance treatment
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use, duration of treatment, and number of previous
treatments for opioid use disorder.
Substance use behavior
We collected data on participants’ substance use using
urine toxicology screens and self-reported assessment
with the MAP. Apart from cigarette smoking, which was
prevalent in the majority of our sample (84.1 %), canna-
bis and alcohol were the most commonly reported sub-
stances of use within the past month (47 and 46 %,
respectively), followed by cocaine (18 %) according to
the MAP (Table 2). Alcohol abuse and dependence were
diagnosed using the M.I.N.I. in 9.5 % of the entire sam-
ple. In the previous three months, the percentage of
Table 2 Substance use behavior among men and women
Sex Adjusted analyses, men vs. women
Outcome Total Men Women OR/MD 95 % CI Adjusted p
n = 492 n = 266 n = 226
Primary
Opioid use in prior 3 months, urine screening; n (%) 239 (48.5) 129 (48.5) 110 (48.5) 1.03 0.71, 1.50 0.911
Secondary
Proportion of use in prior 3 months, urine screening; n (%)
Amphetamines 23 (4.7) 15 (5.6) 8 (3.5) 0.68 0.28, 1.66 0.616
Benzodiazepines 195 (39.6) 95 (35.7) 100 (44.1) 1.60 1.10, 2.33 0.055
Cannabis 114 (23.1) 74 (27.8) 40 (17.6) 0.57 0.37, 0.89 0.056
Cocaine 171 (34.7) 97 (36.5) 74 (32.6) 0.80 0.54, 1.17 0.417
Ecstasy 23 (4.7) 13 (4.9) 10 (4.4) 1.00 0.69, 1.44 0.985
Positive urine screens in prior three months, percent; median (Q1, Q3)
Amphetamines 0 (0, 0) 0 (0, 0) 0 (0, 0) −0.56 −1.11, −0.01 0.141
Benzodiazepines 0 (0, 27.3) 0 (0, 20.0) 0 (0, 30.8) −0.00 −0.27, 0.27 1.008
Cannabis 0 (0, 100.0) 0 (0, 100.0) 0 (0, 50.0) −16.55 −26.90, −6.19 0.011
Cocaine 0 (0, 12.5) 0 (0, 17.7) 0 (0, 7.7) −0.20 −0.52, 0.12 0.397
Opioids 0 (0, 25.0) 0 (0, 27.8) 0 (0, 20.0) −0.21 −0.45, 0.06 0.273
Alcohol use disorder, M.I.N.I.; n (%)
Alcohol dependence 26 (6.3) 14 (6.5) 11 (5.7) 0.81 0.34, 1.90 0.809
Alcohol abuse 13 (3.2) 7 (3.2) 6 (3.1) 0.84 0.27, 2.58 0.844
Smoking behavior, self-report
Current smokers; n (%) 412 (84.1) 212 (80.0) 199 (88.8) 1.93 1.14, 3.27 0.053
Cigarettes smoked daily; mean (SD) 16.9 (10.4) 18.3 (11.7) 15.4 (8.6) −2.81 −4.79, −0.84 0.024
Age of first smoking, years; mean (SD) 15.5 (5.4) 15.5 (5.5) 15.4 (5.3) 0.11 −0.91, 1.12 0.909
Sensitivity analysis
Proportion of use in prior month, MAP; n (%)
Alcohol 227 (46.0) 129 (48.5) 97 (42.9) 0.73 0.50, 1.05 0.213
Heroin 57 (11.5) 35 (13.2) 21 (9.3) 0.54 0.29, 1.00 0.142
Illicit methadone 26 (5.3) 11 (4.1) 14 (6.2) 1.43 0.60, 3.41 0.635
Illicit benzodiazepines 53 (10.7) 29 (10.9) 23 (10.2) 0.90 0.49, 1.66 0.879
Cocaine 89 (18.0) 42 (15.8) 46 (20.4) 1.53 0.91, 2.59 0.241
Crack 57 (11.5) 31 (11.7) 25 (11.1) 0.86 0.42, 1.77 0.839
Amphetamines 32 (6.5) 16 (6.0) 15 (6.6) 0.39 0.10, 1.50 0.330
Cannabis 241 (46.9) 143 (53.8) 88 (41.2) 0.49 0.34, 0.72 <0.001
All analyses have been adjusted for age, methadone dose, and duration of treatment using multivariable regression and for multiple testing error using false
discovery rate; results for binary variables reported as OR and results for continuous variables reported as MD. Variables with non-normal distribution (positive
drug urine screens) have been log transformed for analysis; differences are reported on the log scale. Data for alcohol use disorder measured by the MINI was only
available for 409 participants
Q1 quartile 1, Q3 quartile 3, M.I.N.I. Mini International Neuropsychiatric Interview, SD standard deviation, MAP Maudsley Addiction Profile, OR odds ratio, MD mean
difference, CI confidence interval
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participants with substance use measured by urine toxi-
cology was highest for opioids (48.5 %), followed by ben-
zodiazepines (39.6 %), cocaine (34.7 %), and cannabis
(23.1 %) (Table 2).
Men and women were similar in their rates of opioid
use measured through urine drug screening within the
last 3 months (48.5 % for both). Cannabis use in the past
3 months was less likely among women compared to
men (17.6 % vs. 27.8 %), and women had significantly
fewer positive cannabis urine screens (MD= −16.55; 95 %
CI = −26.90, −6.19; p = 0.011) (Table 2). These results were
consistent when assessed using the MAP (Fig. 2). Women
also reported more frequent use of benzodiazepines com-
pared to men (44.1 % vs. 35.7 %; OR = 1.60; 95 % CI = 1.10,
2.33; p = 0.055).
Although alcohol use was reported more frequently
among men within the past month (48.5 % vs. 42.9 %),
no differences in alcohol-related disorders among men
and women were observed when assessed by the
M.I.N.I. (Table 2). In total, 84 % of the participants were
current smokers, and women reported smoking signifi-
cantly fewer cigarettes daily compared to men (15.4 vs.
18.3; MD = −2.81; 95 % CI = −4.79, −0.84; p = 0.024)
(Table 2). No sex differences among other substance use
were observed.
Health status
Patterns of physical health symptoms demonstrate that
over a third of the sample reported chronic pain
(35.0 %) and a quarter of participants self-reported hepa-
titis C (24.7 %); 10.4 % of the sample reported both. In
contrast, HIV rates were very low (0.8 %, n = 4) (Table 3).
Scores for physical and psychological symptoms, mea-
sured by the MAP, were also low (15.8 and 13.3 out of
40, respectively). Apart from reporting unprotected sex
(42.9 %), health risk behavior was not frequently
reported.
Women endorsed symptoms of physical and psycho-
logical illness more frequently than men, observed by
significantly greater scores on the MAP health do-
mains; 17.4 vs. 14.5 for physical health (MD = 3.18;
95 % CI = 1.83, 4.53; p < 0.001), and 14.7 vs. 12.0 for
psychological health (MD = 2.77; 95 % CI = 1.20, 4.34;
p = 0.007) (Table 3). Women were also significantly
more likely to report a family psychiatric history com-
pared to men (OR = 2.35; 95 % CI = 1.53, 3.62; p < 0.001).
A greater proportion of men reported positive HIV status,
but rates of hepatitis C (27.4 % in men vs. 21.7 % in
women) and chronic pain (35.3 % for men vs. 34.5 % for
women) were equally prevalent among men and women
(Table 3).
Fig. 2 Comparison of substance use behavior among men and women measured by urine drug screening and self-report
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Social functioning
Among our participants, 35.6 % reported current em-
ployment; the median number of days worked in the
past month was 8 for men and 0 for women (Table 3).
Criminal activity within the past month was rare (5.3 %).
Less than half of participants were married (31.8 %) and
a majority reported having children (62.9 %).
Women were less likely to report current employ-
ment compared to men (27.1 % vs. 42.9 %; OR = 0.46;
95 % CI = 0.31, 0.68; p < 0.001) but were more likely
to report having children to care for (73.2 % vs.
54.1 %; OR = 2.88; 95 % CI = 1.90, 4.36; p < 0.001)
(Table 3).
Discussion
The results of this study confirm that trends in illicit
opioid use in Canada are undergoing dynamic changes,
giving rise to a new sociodemographic profile of opioid
users. Compared to past literature, the mean age of
current opioid-dependent patients enrolled in MMT has
increased from 25 to 38 years [21, 32, 33], starting regu-
lar use of opioids later (25 years of age now compared to
21 years in the 1990s) and entering treatment at a later
age than before (currently 32 years compared to 27 years
of age) [17, 21, 33–35]. There has been a 30 % increase
in the proportion of patients who began using opioids
after receiving a prescription from a doctor (20 % in the
1960s to 50 %) [17], usually for the management of
chronic pain, which was present in a third of patients.
We also observed an approximate 60 % decrease in in-
jection drug use [35, 36] and 50 % reduction in rates of
HIV [37]. We have witnessed a gradual deviation from
alcohol use to cannabis [34, 35] and greater rates of
benzodiazepine use [38]. Criminal activity has also de-
clined significantly compared to earlier studies (34 % to
5 % among current opioid users) [35, 38].
Women, who are close to half of the opioid user popu-
lation, experience a higher burden of disease related to
Table 3 Health and social functioning among men and women
Sex Adjusted analyses, men vs. women
Outcome Total Men Women OR/MD 95 % CI Adjusted p
n = 492 n = 266 n = 226
Physical health symptoms
MAP physical symptoms score; mean (SD) 15.8 (7.7) 14.5 (7.8) 17.4 (7.3) 3.18 1.83, 4.53 <0.001
HIV+ status; n (%) 4 (0.8) 4 (1.5) 0 (0) – – –
HCV+ status; n (%) 122 (24.7) 73 (27.4) 49 (21.7) 0.88 0.57, 1.38 0.815
Presence of chronic pain; n (%) 173 (35.0) 94 (35.3) 78 (34.5) 1.31 0.87, 1.97 0.368
Mental health symptoms
MAP psychological symptoms score; mean (SD) 13.3 (8.8) 12.0 (8.4) 14.7 (9.1) 2.77 1.20, 4.34 0.007
Family psychiatric history; n (%) 350 (70.9) 167 (62.8) 182 (80.5) 2.36 1.53, 3.62 <0.001
Health risk behavior in the prior month
Injected drugs; n (%) 53 (10.8) 34 (12.8) 19 (8.4) 0.56 0.30, 1.02 0.146
Unprotected sex; n (%) 212 (42.9) 117 (44.0) 95 (42.0) 0.80 0.55, 1.18 0.426
Employment
Currently employed; n (%) 175 (35.6) 114 (42.9) 61 (27.1) 0.46 0.31, 0.68 <0.001
Paid work in the past month, days; median (Q1, Q3) 0 (0, 16) 8 (0, 20) 0 (0, 4) −0.04 −0.21, 0.13 0.825
Unemployed in the past month, days; median (Q1, Q3) 30 (0, 30) 30 (0, 30) 30 (0, 30) 0.02 −0.04, 0.07 0.828
Criminal activity
Committed crime; n (%) 26 (5.3) 18 (6.8) 8 (3.5) −0.04 −0.08, 0.00 0.148
Interpersonal relations
Married/common-law; n (%) 156 (31.8) 85 (32.1) 70 (31.2) 0.94 0.63, 1.39 0.855
Have children; n (%) 309 (62.9) 144 (54.1) 164 (73.2) 2.88 1.90, 4.36 <0.001
Conflict with partner in the past month, percent; median (Q1, Q3) 0 (0, 7) 0 (0, 3) 0 (0, 10) 0.11 −0.29, 0.50 0.078
Conflict with family in the past month, percent; median (Q1, Q3) 0 (0, 7) 0 (0, 3) 0 (0, 13) 0.42 0.05, 0.80 0.800
All analyses have been adjusted for age, methadone dose, and duration of treatment using multivariable regression and for multiple testing error using false
discovery rate; results for binary variables reported as OR and results for continuous variables reported as MD. Regression model estimates for HIV+ status
were undeterminable
MAP Maudsley Addiction Profile, SD standard deviation, HIV human immunodeficiency virus, HCV: hepatitis C virus, Q1 quartile 1, Q3 quartile 3, OR odds ratio, MD
mean difference, CI confidence interval
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opioid use disorders, with respect to physical and psy-
chological disorders and related symptoms. Women are
more likely to have initiated their substance dependence
through prescription opioids, presumably because of
their higher rates of chronic pain [13]. Indeed, women
are known to experience heightened pain perception and
sensitivity and to have lower levels of opioid analgesia
compared to men [39]. This disparity in opioid prescrib-
ing may also be attributed to the utilization of healthcare
services, as women tend to seek medical care for pain-
related conditions more often than men [40]. Heroin use
is also decreasing as a result of this dependence on pre-
scription opioids among women, and therefore we are
witnessing lower rates of HIV that normally would have
been caused by unsafe heroin injection practices.
Cannabis is now the most prevalent drug of abuse in
North America, even though it remains illegal across
Canada and most of the USA [9]. Given the considerable
rate of chronic pain among participants, it is possible
that cannabis is being used as an adjunctive therapy to
manage pain. Women are less likely to use cannabis
than men, consistent with earlier investigations [41, 42],
which may be attributed to the social stigma associated
with substance use among women. Alternatively, women
may be deterred from using cannabis because of the po-
tential legal implications of this behavior.
Although both alcohol and cocaine use continue to be
problematic among opioid users in MMT, the disparity
that has been seen in the past, with men more likely to
abuse alcohol [33, 34] and women more likely to abuse
cocaine [41–43], is less apparent. Alcohol use has be-
come a concern for women as well, perhaps because of
changes in social roles and attitudes regarding its use
[44, 45]. Also, it is expected that cocaine use is decreas-
ing as it caters primarily to a younger inner-city group
of users, which is characteristic of the former opioid user
population [46].
In comparing self-reported substance use measured by
the MAP to urine toxicology screening in our sensitivity
analysis, we observed considerable under-reporting of
benzodiazepine, cocaine, and opioid use. This finding is
likely a result of social desirability bias, or in the case of
benzodiazepine use, it may also come from a prescrip-
tion for an anxiety-related disorder, although we do not
have the data to confirm this. Overall, objective mea-
sures, such as urine screening, are more reliable than
self-report in identifying drug use in men and women
alike and should be used regularly across all methadone
programs and in future research studies, if possible.
Women experience a heightened vulnerability to the
adverse medical and social consequences of opioid de-
pendence [35, 47] as a result of biological sex character-
istics and socially defined gender roles. Although sex
and gender differences in MMT have been previously
investigated, the literature is limited by the scarcity of
studies, poor methodological quality, and small samples.
A recent systematic review and meta-analysis found 20
studies, many of which were completed over a decade
ago, specifically evaluating methadone treatment out-
comes among men and women [48]. Men were more
likely to be employed and to report a history of legal in-
volvement and alcohol-related problems, and women
were more likely to have used illicit amphetamines
throughout the course of treatment [48]. Sex differences
in physical health [35], comorbid psychiatric conditions
[34, 49, 50], and substance use behavior [33, 34, 41, 42,
51] have also been documented, however findings appear
to be conflicting and generally based on subjective self-
reported measures.
Implications and future directions
Based on the documented changes in the illicit use of opi-
oids, prevention strategies and modifications to available
opioid addiction treatment programs are needed. Current
treatments were initially developed using research from
the 1990s targeting heroin users [52], and thus their ap-
plicability to the growing population of prescription opioid
users is questioned. Guidelines for the treatment of opioid
addiction with methadone [53] require a thorough re-
evaluation to incorporate this transition and the imple-
mentation of new intervention strategies that address the
evolving trends in substance use, health, and social func-
tioning is strongly encouraged.
Women also experience a greater burden of disease
from opioid dependence with respect to medical problems,
health outcomes, and social impairment, elucidating the
need for interventions that address these core areas of
functioning for women [54]. Currently available best prac-
tice guidelines for methadone maintenance treatment in
Canada outline barriers to treatment and highlight areas
for improvement, however these recommendations rely
largely on a small and weak body of evidence comprised of
outdated literature reviews. Similarly, the US federal
guidelines for opioid treatment programs and medication-
assisted treatment developed by Department of Health and
Human Services, Substance Abuse and Mental Health Ser-
vices Administration (SAMHSA) [55] acknowledge that
women require specialized treatment services, however
they are not sufficiently comprehensive as the focus is pri-
marily on pregnancy, physical or sexual abuse, and com-
plex medical problems in women. Furthermore, guidelines
for pharmacologically assisted treatment of opioid depend-
ence set forth by the World Health Organization in 2009
[56] acknowledge areas where women experience particu-
lar difficulty and they emphasize the need for gender-
sensitive treatment services but admit that data on such
programs are sparingly available.
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First, it is necessary to implement appropriate preven-
tion strategies in general but especially for women. As
our results have shown, women are more likely to be ex-
posed to opioids mainly through prescriptions for pain
and other medical conditions. This information can be
used to inform both patients and physicians and in the
assessment of individual benefit or risk of opioid-related
harms. Alternative treatment and therapeutic options
should be considered in the management of pain condi-
tions that require the use of opioid analgesics.
Behavioral therapy and social services can supplement
current pharmacological treatment programs in order to
develop an integrated patient-centered model of care.
Emphasizing the need for fundamental services, such as
vocational counseling, childcare and parenting assistance,
medical assistance, relationship or domestic violence
counseling, and smoking cessation among women is likely
to significantly improve the treatment and management of
opioid use disorder [57]. Similar strategies should be im-
plemented for men in treatment, who experience distinct
sex- and gender-specific characteristics of addiction (i.e.,
HIV, cannabis and amphetamine use). This field of re-
search would benefit from future studies that evaluate the
efficacy of these programs compared to standard care and
assess patient-important outcomes that can be incorpo-
rated into a personalized treatment approach.
Strengths and limitations
This study is limited by its cross-sectional design,
whereby sociobehavioral determinants of opioid use dis-
order were assessed at a single time-point that captured
a period of 30 days (or 3 months in the case of urine
screening). A longer time frame would be more appro-
priate considering the chronicity of the illness and long
treatment duration [58]. In addition, some of the trends
we observed in this study may be attributed to general
population differences rather than the specific context of
opioid users in methadone treatment. Nevertheless, such
factors are still an important consideration for treatment
among men and women.
Despite these limitations, our study had numerous
strengths. We offer a comprehensive update of factors
characterizing a large sample of opioid users receiving
methadone treatment within the Canadian context. Our
study also provides a descriptive profile of sex differ-
ences in methadone treatment, clarifying previous gaps
in the literature. We used an objective measure of urine
toxicology and performed a sensitivity analysis using
self-reported substance use in order to strengthen cred-
ibility in our findings. Based on our results, the response
rate for MMT in this sample is generally comparable to
other studies in the literature (30–80 % of opioid urine
screens generally test negative [53–55]), confirming the
representativeness of this sample. Finally, our data were
derived from a multisite study, whereby standardized
treatment procedures are implemented across all 13
clinic sites, yielding a large representative and geograph-
ically diverse sample.
Conclusions
The results of this study have revealed new patterns in
substance use, health, and social factors among men and
women currently receiving MMT for opioid use disorder
in Ontario, Canada. We have uncovered clinically relevant
sex differences that can be used to advance our under-
standing of addiction and promote strategies for effective
treatment and management of opioid use disorder among
men and women.
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